Gastric motor effects of triptans: open questions and future perspectives.
Sumatriptan is a 5-HT1B/D receptor agonist of documented efficacy in relieving migraine and associated symptoms such as nausea and vomiting. In the past decade, several studies reported an important delay of gastric emptying induced by sumatriptan in healthy humans. The impact of this gastric motor effect of sumatriptan in migraineurs is difficult to predict: a further delay in gastric emptying could be detrimental (i.e. increased nausea and epigastric symptoms) in patients already having delayed gastric emptying. However, in patients with functional dyspepsia, sumatriptan is also reported to improve gastric accommodation to a meal and reduce perception of gastric distention, hence relieving epigastric symptoms. Thus, reduced visceral perception could be a mechanism involved in reducing nausea during a migraine attack. Paradoxically, sumatriptan is reported both to relieve the nausea of a migraine attack and to have nausea as a side effect. Although careful analysis of the time of onset of nausea may offer a clue as to the origin of this symptom, available data do not support definite conclusions, all the more so because the gastric motor effect of second-generation triptans are still unexplored. Taken together, the available evidence warrants further studies to clarify the following issues: first, the mechanism responsible for the gastric motor effect of sumatriptan [receptor subtype(s) involved; central vs peripheral mechanism]; secondly, the effects on gastric motility/visceral sensitivity of second-generation triptans (which are 5-HT1B/D receptor agonists) and more recent selective 5-HT1D receptor agonists (proposed as investigational antimigraine agents with less potential to induce coronary vasoconstriction through 5-HT1B receptors); finally, the possible use of drugs improving gastric accommodation to a meal in the management of those dyspeptic patients with impaired fundic relaxation/altered visceral sensitivity.
Cipolla
G
G
Department of Internal Medicine and Therapeutics, University of Pavia, Italy.
Sacco
S
S
Crema
F
F
Moro
E
E
De Ponti
F
F
Frigo
G
G
D005544:Forecasting; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000494:pharmacology; D009325:Nausea / Q000139:chemically induced; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000494:pharmacology*; D018170:Sumatriptan / Q000009:adverse effects / Q000494:pharmacology*; D014363:Tryptamines; D014839:Vomiting / Q000139:chemically induced
D007211:Indoles; D010880:Piperidines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D018170:Sumatriptan; C106783:naratriptan